FKBPL and breast cancer: Another peptide derivative of FKBPL, AD-01, showed promising activity in BC, reducing ESA+/CD44+/CD24− and ALDH+ cell numbers, self-renewal ability, and expression of OCT4, NANOG, and SOX2 in BC cell lines and xenografts [453].